Arrowhead Pharmaceuticals, Inc.
http://arrowheadpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arrowhead Pharmaceuticals, Inc.
Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.
Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar
Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.
GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform
Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.
Intercept, Madrigal Get Ready For NASH Commercialization
With a 22 June US FDA action date for obeticholic acid in non-alcoholic steatohepatitis, Intercept is thinking ahead to launch plans. Madrigal said it plans a Q2 filing for its NASH drug and hopes to find an ex-US commercial partner.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Ablaris Therapeutics, Inc.
- Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
- Arrowhead Research Corporation
- Calando Pharmaceuticals, Inc.
- Unidym
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice